Pfizer Inc. logo

Pfizer Inc. (PFE)

Market Open
22 Oct, 07:06 PM
NYSE NYSE
$
30. 32
+0.47
+1.5745%
$
168.6B Market Cap
14.55 P/E Ratio
0.68% Div Yield
17.13M Volume
1.43 Eps
$ 29.85
Previous Close
Add Transaction
Day Range
29.88 30.36
Year Range
23.62 30.36
Want to track PFE and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Pfizer and CVS Are Attracting Activists. Healthcare Stocks Could Rebound.

Pfizer and CVS Are Attracting Activists. Healthcare Stocks Could Rebound.

Activists appear to be calling a bottom on the two stocks.

Barrons | 2 years ago
Pfizer (PFE) Stock Drops Despite Market Gains: Important Facts to Note

Pfizer (PFE) Stock Drops Despite Market Gains: Important Facts to Note

In the closing of the recent trading day, Pfizer (PFE) stood at $29.18, denoting a -0.07% change from the preceding trading day.

Zacks | 2 years ago
Pfizer CEO plans to meet activist investor Starboard Value, FT reports

Pfizer CEO plans to meet activist investor Starboard Value, FT reports

Pfizer CEO Albert Bourla plans to meet activist investor Starboard Value, the Financial Times reported on Tuesday, citing people familiar with the matter.

Reuters | 2 years ago
Healthy Returns: What activist Starboard's $1 billion stake means for Pfizer

Healthy Returns: What activist Starboard's $1 billion stake means for Pfizer

Pfizer's troubles may finally be coming to a head. Meanwhile, Hims & Hers is joining S&P SmallCap 600.

Cnbc | 2 years ago
Pfizer Receives $1 Billion From Starboard Value, Stock Rises

Pfizer Receives $1 Billion From Starboard Value, Stock Rises

PFE obtains $1 billion from activist investor Starboard Value. Stock gains on hopes of a plausible turnaround of the struggling pharma giant.

Zacks | 2 years ago
Pfizer Stock Soars as Activist Investor Starboard Takes $1 Billion Stake

Pfizer Stock Soars as Activist Investor Starboard Takes $1 Billion Stake

Pfizer's (PFE, Financial) stock experienced a boost on Monday, surging by 3 %, following the news that activist investor Starboard Value has acquired a substantial stake in the pharmaceutical giant. The investment, valued at approximately $1 billion, could regain investor confidence in Pfizer.

Gurufocus | 2 years ago
Pfizer (PFE) Shares Rise on Starboard Value's $1 Billion Investment

Pfizer (PFE) Shares Rise on Starboard Value's $1 Billion Investment

Pfizer's (PFE, Financial) stock saw an uptick after reports emerged that activist investor Starboard Value has invested $1 billion in the pharmaceutical giant. This development was positively received not only by equity investors but also by bondholders, as evidenced by a narrowing spread on the company's outstanding bonds.

Gurufocus | 2 years ago
Pfizer's bondholders cheer news of activist investor Starboard's $1 billion investment

Pfizer's bondholders cheer news of activist investor Starboard's $1 billion investment

Pfizer Inc.'s stock gained Monday after a report that activist investor Starboard Value has invested $1 billion in the drug company. Bondholders seem to like the news too.

Marketwatch | 2 years ago
Pfizer CEO's Job Is at Risk. A Shot of Discipline Could Help.

Pfizer CEO's Job Is at Risk. A Shot of Discipline Could Help.

As activist Starboard teams up with former Pfizer executives, the pharma giant's lack of focus is in the spotlight.

Wsj | 2 years ago
Watch These Pfizer Price Levels as Stock Gains After Report of Starboard Taking Stake

Watch These Pfizer Price Levels as Stock Gains After Report of Starboard Taking Stake

Pfizer (PFE) shares have gained ground since theThe Wall Street Journal reported over the weekend that activist investor Starboard Value has taken a roughly $1 billion stake in the drug maker and is pushing for changes at the company.

Investopedia | 2 years ago
Pfizer: A 6% Yielding Ultra SWAN Bargain With Upside Potential

Pfizer: A 6% Yielding Ultra SWAN Bargain With Upside Potential

Pfizer, yielding 5.6%, is an Ultra SWAN bargain with upside potential in the next year. Despite $70 billion in debt, Pfizer's A- credit rating and stable cash flow ensure long-term stability and very strong dividend safety. Pfizer's growth outlook includes a 5% long-term growth rate, with a 10% to 11% long-term return potential.

Seekingalpha | 2 years ago
Pfizer, BioNTech win bid to invalidate CureVac's UK COVID vaccine patents

Pfizer, BioNTech win bid to invalidate CureVac's UK COVID vaccine patents

Pfizer and its German partner BioNTech on Tuesday won their attempt to invalidate two of rival CureVac's patents at London's High Court.

Reuters | 2 years ago
Loading...
Load More